Katrin Eckhardt
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova V, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). EClinicalMedicine 2023; 64:102221.
22.09.2023Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
22.09.2023EClinicalMedicine 2023; 64:102221
Novak Urban, Fehr Martin, Schär Sämi, Dreyling Martin, Schmidt Christian, Derenzini Enrico, Zander Thilo, Hess Georg, Mey Ulrich J M, Ferrero Simone, Mach Nicolas, Boccomini Carola, Böttcher Sebastian, Voegeli Michèle, Cairoli Anne, Ivanova Vanesa-Sindi, Menter Thomas, Dirnhofer Stefan, Scheibe Bernhard, Gadient Sandra, Eckhardt Katrin, Zucca Emanuele, Driessen Christoph, Renner Christoph
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
12.07.2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
12.07.2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Hitz F, Rondeau S, Berardi Vilei S, Eckhardt K, Enoiu M, Rothermundt C, Schmidt A, Krasniqi F, Mach N, Caspar C, Samaras P, Cairoli A, Fischer N, Pabst T, Zucca E, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016
28.03.2016Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
28.03.2016Br J Haematol 2016
Hitz Felicitas, Rondeau Stephanie, Berardi Vilei Simona, Eckhardt Katrin, Enoiu Milica, Rothermundt Christian, Schmidt Adrian, Krasniqi Fatime, Mach Nicolas, Caspar Clemens B, Samaras Panagiotis, Cairoli Anne, Fischer Natalie, Pabst Thomas, Zucca Emanuele, Mey Ulrich
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015; 16:1651-8.
02.11.2015Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
02.11.2015Lancet Oncol 2015; 16:1651-8
Stahel Rolf A, Caspar Clemens B, Eckhardt Katrin, Schmid Ralph A, Aebersold Daniel M, Gautschi Oliver, Nagel Wolfgang, Töpfer Michael, Krayenbuehl Jerome, Ribi Karin, Ciernik Llja F, Mordasini Carlo, Zippelius Alfred, Riesterer Oliver, Xyrafas Alexandros, Opitz Isabelle, Beyeler Michael, Ochsenbein Adrian, Früh Martin, Cathomas Richard, Nackaerts Kristiaan, Peters Solange, Mamot Christoph, Weder Walter